Project Romeo
Confidential summary for informational purposes only — not an offer or solicitation. Details provided to qualified parties upon request/NDA.
Opportunity
This opportunity offers a strategic buyer (regional pharma player, OTC/nutraceutical consolidator, or private equity investor) immediate entry into expanding consumer health, food supplements, and branded generics market — featuring high-margin branded assets, marketing-driven growth engine, loyal distribution, and a turnkey sales & regulatory platform for further expansion in Eastern Europe.
The combination of strong profitability, lean operations, and proven brand-building capability positions this as an attractive bolt-on or standalone platform at a compelling valuation.
Company Profile
Established in 2013
Lean, efficient operation with only 15 employees
100% focused on the domestic market via established distribution channels
Ownership: Two shareholders (70%/30% split) – ready for transition
Business Model
Asset-light structure focused on brand ownership, product development, regulatory affairs, marketing, and commercialization Marketing Authorization Holder (MAH) for multiple products, ensuring full regulatory control and flexibility
In-house salesforce:
10 dedicated representatives (6 pharma-focused + 4 medical reps) with proven ability to promote and partner (e.g., successful track record collaborating with AstraZeneca)
Financials
Revenue: $6 million
EBITDA: $1.5 million (robust 26% margin)
Asking Price: $18 million
Portfolio Highlights
Well-branded, strongly positioned portfolio with excellent distributor relationships
16 actively marketed products across growing segments 4 branded generic prescription (RX) medicines
1 OTC product
15 food supplements – including a market-leading brand in the high demand
Omega-3 category
Recent momentum:
Successful launches of one new OTC product and one new branded generic RX product, demonstrating active pipeline and execution capability